We are live on ! Find out more
HIMS icon

Hims & Hers Health

154 hedge funds and large institutions have $643M invested in Hims & Hers Health in 2022 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 53 increasing their positions, 33 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

115% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 13

111% more call options, than puts

Call options by funds: $10.2M | Put options by funds: $4.84M

61% more repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 33

30% more capital invested

Capital invested by funds: $497M → $643M (+$147M)

11% more funds holding

Funds holding: 139154 (+15)

2.73% more ownership

Funds ownership: 55.27%58% (+2.7%)

0% more funds holding in top 10

Funds holding in top 10: 88 (0)

Holders
154
Holders Change
+15
Holders Change %
+10.79%
% of All Funds
2.65%
Holding in Top 10
8
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.14%
New
28
Increased
53
Reduced
33
Closed
13
Calls
$10.2M
Puts
$4.84M
Net Calls
+$5.36M
Net Calls Change
+$1.04M
Name Holding Trade Value Shares
Change
Change in
Stake
MIM
76
MetLife Investment Management
New Jersey
$374K
LA
77
Legacy Advisors
Pennsylvania
$357K +$193K +32,026 +100%
Legal & General Group
78
Legal & General Group
United Kingdom
$327K +$19.6K +3,246 +6%
AIG
79
American International Group
New York
$322K +$4.9K +813 +1%
Deutsche Bank
80
Deutsche Bank
Germany
$294K -$61.8K -10,255 -16%
Invesco
81
Invesco
Georgia
$286K +$61.4K +10,188 +25%
QC
82
Quadrature Capital
United Kingdom
$269K +$290K +48,212 New
Walleye Trading
83
Walleye Trading
New York
$267K +$15.1K +2,512 +6%
Manulife (Manufacturers Life Insurance)
84
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$263K +$205 +34 +0.1%
VOYA Investment Management
85
VOYA Investment Management
Georgia
$261K +$16.1K +2,670 +6%
CAM
86
Cresset Asset Management
Illinois
$260K -$125K -20,753 -31%
Susquehanna International Group
87
Susquehanna International Group
Pennsylvania
$239K -$2.16M -358,544 -89%
Russell Investments Group
88
Russell Investments Group
United Kingdom
$227K +$245K +40,700 New
Principal Financial Group
89
Principal Financial Group
Iowa
$222K +$4.36K +723 +2%
ASRS
90
Arizona State Retirement System
Arizona
$180K +$1.56K +259 +0.8%
Handelsbanken Fonder
91
Handelsbanken Fonder
Sweden
$179K
IC
92
IEQ Capital
California
$173K
BCM
93
Bayesian Capital Management
New York
$168K -$163K -27,000 -47%
Janus Henderson Group
94
Janus Henderson Group
United Kingdom
$168K +$89K +14,765 +95%
SG Americas Securities
95
SG Americas Securities
New York
$168K +$89.7K +14,884 +97%
BWP
96
Baldwin Wealth Partners
Massachusetts
$154K
BP
97
BBR Partners
New York
$149K
LOAMU
98
Lombard Odier Asset Management (USA)
New York
$144K -$78.6K -13,048 -34%
I
99
INVST
Indiana
$135K
HighTower Advisors
100
HighTower Advisors
Illinois
$133K +$7.01K +1,164 +5%

HIMS Hedge Fund Activity: Q3 2022 in Review

154 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Hims & Hers Health (HIMS) for Q3 2022, worth a combined $643M — up 30% from $497M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new HIMS positions and 13 closed out — a net gain of 15 holders — while 53 added to existing stakes and 33 trimmed.

The largest buyer was Nuveen, adding an estimated $9.05M. The largest seller was J. Goldman & Co, cutting an estimated $6.25M.

  • 154 institutional investors held Hims & Hers Health (HIMS) as of Q3 2022, up from 139 in Q2 2022.
  • Funds reported $643M of Hims & Hers Health stock for Q3 2022, up 30% quarter-over-quarter.
  • 28 funds opened new Hims & Hers Health positions in Q3 2022 and 13 closed out, a net change of +15 holders.
  • The largest Hims & Hers Health buyer in Q3 2022 was Nuveen, an estimated $9.05M added.
  • The largest Hims & Hers Health seller in Q3 2022 was J. Goldman & Co, an estimated $6.25M sold.

Based on aggregated 13F filings for Q3 2022.